Sanofi-aventis 1Q

1Q Revenues: $9.4 billion (+3%)

1Q Earnings: $2.9 billion (flat)

Comments: Pharmaceutical sales were $8.6 billion (-1%). Lovenox sales were $1.0 billion (+1%). Lantus sales were $993.0 million (+27%). Plavix sales were $910.6 million (+4%). Taxotere sales were $709.8 million (+8%). Eloxatin sales were $457.3 million (-7%) with European sales impacted by generic competition. Aprovel sales were up 11% to $417.4 million. Apidra sales were up 43% to $41.2 million. Vaccine sales were up 9% to $833.5 million. Earnings were up 16% in local currencies.